PharmaShots | Incisive News in 3 Shots

Subscribe Now

GBT

GBT Receives MHRA’s Marketing Authorization for Oxbryta (voxelotor) to Treat Hemolytic Anemia in Patients with Sickle Cell Disease Aged ≥12 Years in Great Britain

GBT Receives MHRA’s Marketing Authorization for Oxbryta (voxelotor) to Treat Hemolytic Anemia in Patients with Sickle Cell Disease...

July 27, 2022

GBT Reports Initiation of the P-II/III Study of GBT601 for the Treatment of Sickle Cell Disease

GBT Reports Initiation of the P-II/III Study of GBT601 for the Treatment of Sickle Cell Disease

June 30, 2022

GBT’s Oxbryta (voxelotor) Receives EC’s Approval for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease

GBT’s Oxbryta (voxelotor) Receives EC’s Approval for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease

February 16, 2022

GBT’s Oxbryta (voxelotor) Receives CHMP Positive Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease

GBT’s Oxbryta (voxelotor) Receives CHMP Positive Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Diseas...

December 20, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us